Deep Learning on Amyloid Positons Emission Tomography

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-99
SponsorCentral Hospital, Nancy, France

About this trial

Reducing injected dose and/or acquisition time in amyloid PET imaging would improve comfort, radiation safety and cost-effectiveness in diagnosis and follow-up of patients. This study evaluates the impact of a deep learning-based noise reduction algorithm on visual analysis and Centiloid quantification when simulating reduced injected doses of \[18F\]flutemetamol.

Eligibility criteria

Qualifiers

Patients with objective cognitive impairment,

Referred to our department for a cerebral [¹⁸F]flutemetamol positron emission tomography scan between January 1, 2023 and July 1, 2025,

Disqualifiers

Patient have objected to the use of their data.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

3
CHRU NANCY Brabois, nuclear medicine department54511, Vandœuvre-lès-Nancy France
Nancy's hospital54511, Vandœuvre-lès-Nancy France
Nuclear medicine department CHRU de NANCY Brabois54511, Vandœuvre-lès-Nancy France

Sponsors and collaborators

Central Hospital, Nancy, France

Lead sponsor